Last Updated:
Searching
Create account to add to watchlist!

LAVA Medtech Acquisition Corp. - LVAC

  • Commons

    $9.88

    +0.10%

    LVAC Vol: 20.4K

  • Warrants

    $0.47

    -0.43%

    LVACW Vol: 43.3K

  • Units

    $10.10

    +0.00%

    LVACU Vol: 700.0

Average: 0
Rating Count: 0
You Rated: Not rated

Please log in to rate.

SPAC Stats

Market Cap: 0.0
Average Volume: 0.0
52W Range: $0.00 - $0.00
Weekly %: +0.00%
Monthly %: +0.00%
Inst Owners: 0

Info

Target: Searching
Days Since IPO: 89
Unit composition:
Each unit has an offering price of $10.00 and consists of one share of our Class A common stock and one-half of one redeemable warrant
Trust Size: 10000000.0M

Management

Our officers, directors and director nominees are as follows: Name ​ ​ Age ​ ​ Title ​ Anthony Natale ​ ​ ​ ​ ​ Chief Executive Officer and Director ​ Richard Emmitt ​ ​ ​ ​ ​ Chairman and Director Nominee ​ Gerry Brunk ​ ​ ​ ​ ​ President and Director ​ Daniel Hetu ​ ​ ​ ​ ​ Executive Vice President ​ Vasco Larcina ​ ​ ​ ​ ​ Chief Financial Officer ​ Peter van der Velden ​ ​ ​ ​ ​ Director nominee ​ Fritz A. LaPorte ​ ​ ​ ​ ​ Director nominee ​ Anthony “Tony” Natale, MD, MBA, our Chief Executive Officer and a Director, has over 20 years of experience in healthcare venture capital and MedTech entrepreneurship as a physician, inventor, founder, operator, and investor. As a Managing Partner at Aperture Venture Partners since 2010, Dr. Natale focuses on identifying and investing in high-potential MedTech companies. He works alongside entrepreneurs to build out management teams, establish effective corporate governance, and implement successful product development, commercialization, and exit strategies. Prior to Aperture, Dr. Natale was a partner at Prism Venture Works from 2006 to 2010, and MDS Capital from 2002 to 2006, Lumira’s predecessor firm, where he made and managed investments in the MedTech sector. He has held pivotal roles at venture-backed healthcare companies throughout his career, including currently as Executive Chairman at ENT Specialty Partners and Acting Chief Executive Officer at XII Medical, and previously as co-founder and / or founding investor at MAKO Surgical (IPO, subsequently acquired by Stryker), Avedro (IPO, subsequently acquired by Glaukos), ENTrigue Surgical (acquired by Arthrocare/Smith & Nephew), Xlumena (acquired by Boston Scientific), Spirox (acquired by Entellus Medical), and Entellus Medical (acquired by Stryker), and as an investor in many additional companies that have had successful exits, including Inspire Medical (NYSE: INSP), Axonics (Nasdaq: AXNX), BioHaven (Nasdaq: BHVN) and Otonomy (Nasdaq: OTIC). Dr. Natale currently serves on the board of directors of Venus Concept Inc. (Nasdaq: VERO) Dr. Natale trained in general surgery and otolaryngology/head and neck surgery at the University of Connecticut and Hartford Hospital. He received his BA from the University of Virginia, MD from the University of Florida, and MBA from Yale University. Dr. Natale is well qualified to serve on our Board of Directors because of his extensive experience in healthcare venture capital and his many years of management and leadership experience. Richard “Dick” Emmitt, MBA, our Chairman and Director Nominee, is widely regarded as one of the most experienced and successful investors in the medical device industry. Mr. Emmitt is a Senior Partner of InnovaHealth Partners, a New York-based private equity firm focused on the MedTech industry. He also is a General Partner and a co-founder in 1988 of The Vertical Group, a New Jersey-based MedTech focused investment firm. Mr. Emmitt’s background includes all stages of private equity, venture capital, and pubic equity markets. Among his former investments and board of director memberships are companies in virtually all major sectors of the MedTech industry: American Medical Systems (acquired by Endo Pharma and now a part of Boston Scientific); ENTrigue Surgical (acquired by Arthrocare/Smith & Nephew); ev3 (acquired by Covidien/Medtronic); Galil Medical (acquired by BTG/Boston Scientific); Lifecell (acquired by KCI); OsteoBiologics (acquired by Smith & Nephew); SciMed Life Systems (acquired by Boston Scientific); Tornier (acquired by Wright Medical); Velocimed (acquired by Saint Jude); Wright Medical (acquired by Stryker); and Xomed Surgical 124 TABLE OF CONTENTS (acquired by Medtronic). Additionally, his investments also include Outset Medical (Nasdaq: OM) and Silk Road Medical (Nasdaq: SILK). Prior to his career as a venture capital and private equity investor, Mr. Emmitt was an investment analyst recognized as one of the leading experts on the health care industry by Institutional Investor Magazine. Mr. Emmitt received a BA in Economics from Bucknell University and an MBA from The Rutgers School of Business. Mr. Emmitt is well qualified to serve on our Board of Directors because of his experience as a director of multiple public companies and his over 40 years of management and leadership positions in the medical device industry. Gerry Brunk, MBA, our President and a Director, is a Managing Director and Co-head of the MedTech practice at Lumira. With over 28 years of investment, consulting and entrepreneurial experience in the healthcare industry, Mr. Brunk has helped build MedTech and biotech companies at all stages of development. He manages Lumira’s Boston office, which he established when he joined MDS Capital in 2002. Mr. Brunk has been responsible for Lumira’s investments in Bardy Diagnostics MAKO Surgical (IPO, subsequently acquired by Stryker), Cardiac Dimensions, Corvia Medical, Endotronix, HistoSonics, KAI Pharmaceuticals (acquired by Amgen), Pharmasset (acquired by Gilead Sciences), Satsuma Pharmaceuticals (Nasdaq: STSA) and Engage Therapeutics (acquired by UCB), among others. Prior to joining Lumira, Mr. Brunk was an entrepreneur in the life sciences sector, founding and serving in a variety of management and board capacities at several venture capital-funded companies. Earlier in his career, he was an engagement manager in The Boston Consulting Group’s healthcare practice, where he advised pharmaceutical and MedTech companies on strategic and operational issues including portfolio management, new product launches, R&D productivity, mergers and acquisitions. Mr. Brunk began his career as a member of the investment banking group of Credit Suisse First Boston where his clients included both public and private healthcare companies. He serves on the Board of Directors of Southeast Life Sciences, the review board of the Ivy Foundation Biomedical Innovation Fund at the University of Virginia, and is a mentor for the Stanford University Biodesign program. He received his BA from the University of Virginia and MBA from Stanford University Graduate School of Business. Mr. Brunk is well qualified to serve on our Board of Directors because of his extensive management and investment experience in the healthcare and life sciences sectors. Daniel Hétu, MD, MBA, our Executive Vice President, is a Managing Director and Co-head of the MedTech practice at Lumira, and has been since 2007. With over 20 years of investment banking, corporate development, and licensing and investment experience, Dr. Hétu has been involved with life sciences companies at all stages of development in North America and overseas. He manages Lumira’s Montreal office and has invested in and served on the boards of numerous companies, including OpSens Medical (TSX: OPS), U-Systems (acquired by GE Healthcare), Cardiac Dimensions, IMV (TSX: IMV), Resonant Medical (acquired by Elekta) and XyloCor Therapeutics. As an experienced senior executive with expertise in financing and corporate business development, Dr. Hétu previously spent 10 years at Shire Pharmaceuticals and at Biochem Pharma prior to its acquisition by Shire. As Vice President of Business Development (North America) and Vice President of Corporate Development, he led several financing, licensing and M&A transactions in the therapeutics, vaccine, and diagnostics sectors. Prior to joining Biochem Pharma, Dr. Hétu was an investment banker at Burns Fry (now BMO Nesbitt Burns) where he was involved in M&A and financing transactions across various industrial sectors. He received his MD from Université de Sherbrooke and MBA from HEC Montréal. Vasco Larcina, CPA, CA, our Chief Financial Officer, has over 20 years of senior financial management and audit experience. He is Chief Financial Officer at Lumira where he is responsible for the financial management of the firm and the investment funds it manages, and has been since the 125 TABLE OF CONTENTS firm’s inception in 2007. Mr. Larcina oversees financial and legal operations, ensuring that the appropriate controls are in place to manage the activities of Lumira and its managed funds through the strategic evaluation, development and implementation of financial policies, systems and procedures developed in consideration of external reporting, risk, and governance, as well as, regulatory and tax compliance. Prior to joining Lumira, Mr. Larcina worked as an external auditor with KPMG and has gained internal audit and operational audit experience with Enbridge Gas Distribution, a regulated public utility company, where he provided the internal control input for a major customer information system development project. He received his HBA from the Ivey School of Business at the University of Western Ontario and is a member of the Chartered Professional Accountants of Ontario. Director Nominees Peter van der Velden, MBA, MSc., one of our Director Nominees, is a venture capital veteran who for the past 31 years has been involved in building innovative, technology-centric companies from start-up through to expansion. In 2005, he joined MDS Capital as Chief Executive Officer and after restructuring the firm, he led its subsequent buyout from MDS Laboratory Services. Mr. van der Velden has invested in and helped to build MedTech and biotech companies at all stages of development. He joined Lumira in 2007 and is based in Toronto, Canada. Mr. van der Velden is currently Lumira’s Managing General Partner, responsible for the day-to-day operations of the business, fund raising, and human resources. Along with Mr. Brunk, Mr. van der Velden has been responsible for Lumira’s investments in Bardy Diagnostics and HistoSonics. He led or managed the firm’s investments in Alveolus (acquired by Merit Medical), Spinal Kinetics (acquired by Orthofix), Aurinia Pharmaceuticals (Nasdaq: AUPH), Forbius (Acquired by Bristol Myers Squibb) and his is currently on the boards of Exact Imaging, AmacaThera, Edesa Biotech (Nasdaq: EDSA), and Medexus Pharmaceuticals (TSXV: MDP.V) Mr. van der Velden is a frequently solicited lecturer at universities and conferences on themes related to venture capital, innovation and healthcare. He has actively worked with the Canadian Federal and Provincial governments on policy matters related to venture capital and healthcare innovation. In addition to investee company board roles, he has been very active on a wide variety of stakeholder and industry boards and advisory groups, including as, President and Chairman of the Canadian Venture and Private Equity Association. Mr. van der Velden’s past board and advisory roles include: the Ontario Health Innovation Council, the World Health Innovation Network, the SickKids Commercialization Advisory Board, the Office of the Chief Health Innovation Strategist, the Ontario Scale-up Vouchers Program, and Life Sciences Ontario. Prior to joining Lumira, Mr. van der Velden ran a boutique merchant bank (Fusion Capital Partners), was a partner in a buyout partnership (Bedford Capital) and served as Vice President Business Development for a venture capital-backed drug delivery company, Hyal Pharmaceutical Corp. He started his career with Connaught Laboratories, Inc., a Canadian vaccine manufacturer and from there transitioned to an investing role at Vencap Equities Alberta Ltd., a venture capital firm. Mr. van der Velden received his MBA from the Schulich School of Business and his M.Sc. and B.Sc from Queen’s University. Mr. van der Velden is well qualified to serve on our Board of Directors because of his many years of experience in venture capital investing and portfolio company management leadership positions. Fritz A. LaPorte, one of our Director Nominees, is a Partner at Dovere Advisory Group, LLC, which he co-founded in October 2014 to guide earlier stage, growth companies, primarily operating in the medical devices and healthcare sectors, in creating and sustaining value while concurrently reducing risk. Mr. LaPorte co-founded MAKO Surgical, an orthopedic surgical robotics company, in 126 TABLE OF CONTENTS November 2004, and served as Senior Vice President, Chief Financial Officer, and Treasurer through its IPO and eventual acquisition by Stryker in 2013. Mr. LaPorte subsequently served as Vice President and Chief Financial Officer of Stryker Corporation — Stryker MAKO Business Unit from December 2013 to June 2014 to assist in the integration of MAKO into Stryker. He also sits on the board of directors at Venus Concept Inc. (Nasdaq: VERO), a leading medical aesthetics company, where he also serves as Audit Committee Chair, and Holy Cross Hospital in Fort Lauderdale, Florida where he also serves as a member of the finance committee. Mr. LaPorte holds a BBA in Accounting from Florida Atlantic University. Mr. LaPorte is well qualified to serve on our Board of Directors because of his extensive leadership experience in healthcare and his experience as a board member of a public company. Number, Terms of Office, Actions and Election of Officers and Director Upon the effectiveness of the registration statement of which this prospectus forms a part, we expect that our board of directors will consist of five members. Holders of our founder shares will have the right to elect all of our directors prior to consummation of our initial business combination and holders of our public shares will not have the right to vote on the election of directors during such time. These provisions of our amended and restated certificate of incorporation may only be amended if approved by holders of at least 90% of our outstanding common stock entitled to vote thereon. Each of our directors will hold office for a two-year term. Subject to any other special rights applicable to the stockholders, any vacancies on our board of directors may be filled by the affirmative vote of a majority of the remaining directors of our board or by a majority of the holders of our common stock (or, prior to our initial business combination, a majority of the holders of our founder shares). We may not hold an annual meeting of stockholders until after we consummate our initial business combination. In accordance with Nasdaq corporate governance requirements, we are not required to hold an annual meeting until no later than one year after our first fiscal year end following our listing on Nasdaq. Subject to any other special rights applicable to the stockholders, any vacancies on our board of directors may be filled by the affirmative vote of a majority of the directors present and voting at the meeting of our board that includes any directors representing our sponsor then on our board, or by a majority of the holders of our founder shares. Our officers are elected by the board of directors and serve at the discretion of the board of directors, rather than for specific terms of office. Our board of directors is authorized to appoint persons to the offices set forth in our bylaws as it deems appropriate. Our bylaws will provide that our officers may consist of a Chairman, Chief Executive Officer, President, Chief Financial Officer, Vice Presidents, Secretary, Assistant Secretaries, Treasurer and such other offices as may be determined by the board of directors. Director Independence Nasdaq listing standards require that a majority of our board of directors be independent. An “independent director” is defined generally as a person other than an officer or employee of the company or its subsidiaries or any other individual having a relationship which in the opinion of the company’s board of directors, would interfere with the director’s exercise of independent judgment in carrying out the responsibilities of a director. Upon the effectiveness of the registration statement of which this prospectus forms a part, we expect to have three “independent directors” as defined in Nasdaq listing standards and applicable SEC rules. Our audit committee will be entirely composed of independent directors meeting Nasdaq’s additional requirements applicable to members of the audit committee. Our independent directors will have regularly scheduled meetings at which only independent directors are present. 127 TABLE OF CONTENTS Executive Officer and Director Compensation We may pay our sponsor or any of our existing officers or directors, or any entity with which they are affiliated, a finder’s fee, consulting fee or other compensation in connection with identifying, investigating and completing our initial business combination, which may be paid from the proceeds held in the trust account upon consummation of an initial business combination. These individuals and entities will be reimbursed for any reasonable out-of-pocket expenses incurred in connection with activities on our behalf such as identifying potential target businesses and performing due diligence on suitable business combinations. Our audit committee will review on a quarterly basis all payments that were made by us to our sponsor, officers or directors, advisors or our or their affiliates. Any such payments prior to an initial business combination will be made using funds held outside the trust account. Other than quarterly audit committee review of such payments, we do not expect to have any additional controls in place governing our reimbursement payments to our directors and executive officers for their out-of-pocket expenses incurred in connection with identifying and consummating an initial business combination. After the completion of our initial business combination, directors or members of our management team who remain with us may be paid consulting, management or other fees from the combined company. All of these fees will be fully disclosed to stockholders, to the extent then known, in the tender offer materials or proxy solicitation materials furnished to our stockholders in connection with a proposed business combination. It is unlikely the amount of such compensation will be known at the time such materials are distributed, because the directors of the post-combination business will be responsible for determining executive officer and director compensation. Any compensation to be paid to our officers will be determined by a compensation committee constituted solely by independent directors. The existence or terms of any employment or consulting arrangements may influence our management’s motivation in identifying or selecting a target business but we do not believe that the ability of our management to remain with us after the consummation of our initial business combination will be a determining factor in our decision to proceed with any potential business combination. We are not party to any agreements with our officers and directors that provide for benefits upon termination of employment. Committees of the Board of Directors Upon the effective date of the registration statement of which this prospectus forms a part, our board of directors will have two standing committees: an audit committee and a compensation committee. Subject to phase-in rules and a limited exception, the rules of Nasdaq and Rule 10A-3 of the Exchange Act require that the audit committee of a listed company be comprised solely of independent directors. Subject to phase-in rules and a limited exception, the rules of Nasdaq require that the compensation committee of a listed company be comprised solely of independent directors. Audit Committee Upon the effectiveness of the registration statement of which this prospectus forms a part, we will establish an audit committee of the board of directors. Under Nasdaq listing standards and applicable SEC rules, we are required to have a

SEC Filings

Form Type Form Description Filing Date Document Link
8-K FORM 8-K 2021-12-16 https://www.sec.gov/Archives/edgar/data/1855450/000110465921150449/tm2135592d1_8k.htm
10-Q FORM 10-Q 2021-12-10 https://www.sec.gov/Archives/edgar/data/1855450/000110465921148683/lvac-20211231x10q.htm
SC 13G 2021-11-08 https://www.sec.gov/Archives/edgar/data/1855450/000093583621000608/lavamedtech13g.htm
8-K FORM 8-K 2021-11-04 https://www.sec.gov/Archives/edgar/data/1855450/000110465921134509/tm2113928d17_8k.htm
8-K FORM 8-K 2021-11-01 https://www.sec.gov/Archives/edgar/data/1855450/000110465921132261/tm2113928d16_8k.htm
424B4 424B4 2021-10-28 https://www.sec.gov/Archives/edgar/data/1855450/000110465921130896/tm2113928-12_424b4.htm
EFFECT 2021-10-26 https://www.sec.gov/Archives/edgar/data/1855450/999999999521004038/xslEFFECTX01/primary_doc.xml
3 OWNERSHIP DOCUMENT 2021-10-26 https://www.sec.gov/Archives/edgar/data/1855450/000110465921130083/xslF345X02/tm2130876-8_3seq1.xml
3 OWNERSHIP DOCUMENT 2021-10-26 https://www.sec.gov/Archives/edgar/data/1855450/000110465921130081/xslF345X02/tm2130876-7_3seq1.xml
3 OWNERSHIP DOCUMENT 2021-10-26 https://www.sec.gov/Archives/edgar/data/1855450/000110465921130076/xslF345X02/tm2130876d6_3seq1.xml
3 OWNERSHIP DOCUMENT 2021-10-26 https://www.sec.gov/Archives/edgar/data/1855450/000110465921130075/xslF345X02/tm2130876-5_3seq1.xml
3 OWNERSHIP DOCUMENT 2021-10-26 https://www.sec.gov/Archives/edgar/data/1855450/000110465921130074/xslF345X02/tm2130876-4_3seq1.xml
3 OWNERSHIP DOCUMENT 2021-10-26 https://www.sec.gov/Archives/edgar/data/1855450/000110465921130072/xslF345X02/tm2130876-3_3seq1.xml
3 OWNERSHIP DOCUMENT 2021-10-26 https://www.sec.gov/Archives/edgar/data/1855450/000110465921130071/xslF345X02/tm2130876-2_3seq1.xml
3 OWNERSHIP DOCUMENT 2021-10-26 https://www.sec.gov/Archives/edgar/data/1855450/000110465921130070/xslF345X02/tm2130876-1_3seq1.xml
CERT 2021-10-26 https://www.sec.gov/Archives/edgar/data/1855450/000135445721001217/8A_Cert_LVAC.pdf
8-A12B 8-A12B 2021-10-25 https://www.sec.gov/Archives/edgar/data/1855450/000110465921129489/tm2113928d14_8a12b.htm
CORRESP 2021-10-22 https://www.sec.gov/Archives/edgar/data/1855450/000110465921128888/filename1.htm
CORRESP 2021-10-22 https://www.sec.gov/Archives/edgar/data/1855450/000110465921128886/filename1.htm
CORRESP 2021-10-15 https://www.sec.gov/Archives/edgar/data/1855450/000110465921126842/filename1.htm
S-1/A S-1/A 2021-10-15 https://www.sec.gov/Archives/edgar/data/1855450/000110465921126839/tm2113928-9_s1a.htm
UPLOAD 2021-10-08 https://www.sec.gov/Archives/edgar/data/1855450/000000000021012307/filename1.pdf
S-1 S-1 2021-10-01 https://www.sec.gov/Archives/edgar/data/1855450/000110465921122070/tm2113928-7_s1.htm
DRS/A 2021-08-23 https://www.sec.gov/Archives/edgar/data/1855450/000110465921108628/filename1.htm
DRS 2021-04-29 https://www.sec.gov/Archives/edgar/data/1855450/000110465921057749/filename1.htm